FDA grants De Novo classification for innovative analytic technology developed at MCIRCC
Source: MCIRCC
Michigan Medicine spin-off company, Fifth Eye, is launching their first product, the Analytic for Hemodynamic Instability (AHI).
News
Keep up to date with the latest from Fifth Eye.
FDA grants De Novo classification to Fifth Eye’s continuous hemodynamic status monitoring tool
Source: MobiHealthNews
The Analytic for Hemodynamic Instability tool can identify hemodynamic instability with 96% sensitivity and detects stable patients with 85% specificity.
FDA Grants De Novo to ML-based, Real-time Indicator of Patient Deterioration
Source: Fifth Eye Inc.
Fifth Eye’s noninvasive tool is the first to provide continuous monitoring of hemodynamic status using a single ECG lead
Using Predictive Analytics to Stay Ahead of Patient Deterioration
Source: HealthITAnalytics
Researchers from Michigan Medicine and Fifth Eye have developed a predictive analytics tool that can alert providers which patients are at risk of deteriorating.
Analytics Tool Offers Early Warning of Hemodynamic Instability
Source: Healthcare Innovation
The venture capital-backed startup, Ann Arbor-based Fifth Eye, has developed a noninvasive clinical tool called Analytic for Hemodynamic Instability (AHI), which it says is the first solution to establish real-time streaming data for early onset hemodynamic instability. A research study on the solution was first published in November 2020 by the International Journal of Medical Health Sciences and was recently awarded “Best Paper” at the 2020 International Conference on Health Analytics. The company is now awaiting approval from the U.S. Food & Drug Administration before marketing it to other health systems.
Promising New Technology Identifies Certain Deteriorating Critical Care Patients Before “Crash”
Source: Fifth Eye Inc.
New peer-reviewed research by Fifth Eye and Michigan Medicine awarded best paper at international conference on health analytics.
New research shows a groundbreaking clinical tool, in development by Fifth Eye and Michigan Center for Integrative Research in Critical Care (MCIRCC), can reliably alert clinicians that a patient is at risk of developing hemodynamic instability — one of the most common causes of death for critically injured or ill patients — well before they deteriorate. This allows for earlier intervention before the patient progresses to cardiac arrest, organ injury, or other serious adverse events.
Fifth Eye, HT Mobile Apps, Poisera and Plymouth Growth Give Back to the Community by Joining the Ann Arbor Entrepreneurs Fund
The Ann Arbor Entrepreneurs Fund (A2EF) supports entrepreneurs and investors by connecting them with their peers and the community and provides a platform for them to give back to Washtenaw County through equity donations. A2EF is excited to recognize the leadership and generosity of Jen Baird, Kathleen Craig, Marianna Kerppola and Evan Ufer, in pledging 1% of their equity to the A2EF endowment fund at the Ann Arbor Area Community Foundation.
After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval
Fifth Eye’s software is designed to act as an early warning system to predict when a patient might be in imminent trouble, based on their electrocardiogram (ECG) data. When the heart overcompensates for other trouble in the body, the signs are subtle, Baird says, but they have detectable mathematical characteristics, which helps the company’s software to assess the patient’s condition.
Fifth Eye Inc. raises $11.5M Series A funding round led by Arboretum Ventures and Cultivation Capital
Fifth Eye uses continuous physiologic waveforms to build clinical early warning systems that enable proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay and reduce healthcare costs. The financing will be used to secure FDA clearance of Fifth Eye’s first product, support clinical studies with multiple health systems, and enable commercial launch of the company’s first product, the Analytic for Hemodynamic Instability.
-
Critical care/ED MD
The key value proposition is in accurately predicting problems before they happen to aid in the recognition and rescue of the deteriorating patient…this makes it a novel next generation monitoring and predicting tool.
-
Chief Medical Officer
We have a couple of teams dabbling in "early warning" models but they have not distilled it down to a single ECG lead!
-
Chief Medical Officer
The linkage of an early response team with this technology would have a very high likelihood of being associated with a significant survival benefit.
-
Chair, Vascular Surgery
This is an amazing breakthrough! I can see so many applications within the hospital. I would like to get you connected to our innovation center so that we could be involved in its development.
-
Chief Medical Officer
Yes, this is a game-changer. The industry absolutely needs a better detection system for hemodynamic instability.
-
Nurse Trainer
All I can say is wow! That is awesome.
